Sanofi to acquire immuno-oncology company Synthorx for $2.5B
The San Diego-based biotech is developing IL-2 therapeutics for cancers as well as autoimmune disorders. Its lead candidate, THOR-707, is in a Phase I/II study in solid tumors.
The San Diego-based biotech is developing IL-2 therapeutics for cancers as well as autoimmune disorders. Its lead candidate, THOR-707, is in a Phase I/II study in solid tumors.
Interleukin-2 has been plagued by low responses and scary side effects but Synthorx is adding synthetic amino acids and a polymer to the treatment in an effort to make it a more effective cancer therapy
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The money will be used to develop products by leveraging its synthetic amino acid platform as well as to hire chief business and scientific officers.